Why Beam Therapeutics Climbed 64.5% in June
Shares of Beam Therapeutics (NASDAQ: BEAM) jumped almost 65% last month according to S&P Global Market Intelligence. The move was in concert with other gene editing companies after Intellia Therapeutics and Regeneron announced results from a phase 1 study. The data indicated the pair had successfully used CRISPR-Cas9 to treat a rare liver disease.